PRELUDE CAPITAL MANAGEMENT, LLC
Position in CTMX — CytomX Therapeutics, Inc.
CIK 1387508
NEW YORK, NY
Position in CTMX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$572,986
-$306,814 QoQ
Shares Held
121,912
-41.0% QoQ
Ownership
0.056%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
5 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in CTMX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRELUDE CAPITAL MANAGEMENT, LLC holds $41,687,806 across 71 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
58,590 | $7,776,650 | |
| 2 | TECH |
BIO-TECHNE Corp
|
91,696 | $6,478,322 | |
| 3 | PGEN |
Precigen, Inc.
|
882,267 | $5,028,921 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
113,104 | $4,002,750 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
10,997 | $2,059,518 | |
| 6 | QURE |
uniQure N.V.
|
32,229 | $1,484,467 | |
| 7 | MDXG |
Mimedx Group, Inc.
|
215,239 | $828,670 | |
| 8 | CGON |
CG Oncology, Inc.
|
10,811 | $768,121 |
All Filings in CTMX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $572,986 | 121,912 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $879,800 | 206,526 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $658,817 | 206,526 | Shares | Other | 2025-11-14 | |
| 2020-09-30 | $11,305 | 1,700 | Shares | Other | 2020-11-16 | |
| 2020-06-30 | $3,332 | 400 | Shares | Other | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||